CONSTANCE HARTGROVE: Open Payments
NPI 1407307473 · COLUMBUS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,137 in 44 payments from 14 companies in 2025. Trend: 2023 $1,945 · 2024 $2,180 · 2025 $2,137
Food & beverage: $2,137
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $441 |
| ABBVIE INC. | 17 | $406 |
| Janssen Pharmaceuticals, Inc | 2 | $239 |
| Axsome Therapeutics, Inc. | 4 | $238 |
| Neurocrine BioSciences, Inc. | 3 | $165 |
| Braeburn Inc. | 2 | $142 |
| Supernus Pharmaceuticals, Inc. | 1 | $126 |
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Gilead Sciences, Inc. | 3 | $55 |
Products named: CAPLYTA, VRAYLAR, SPRAVATO, Auvelity, INGREZZA, BRIXADI, Qelbree, COBENFY.
Industry payments across OH — which companies pay providers there.
